Bluejay Diagnostics (Bluejay Diagnostics) EBIT : $-10.06 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Bluejay Diagnostics EBIT?

Bluejay Diagnostics's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was $-2.43 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was $-10.06 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bluejay Diagnostics's annualized ROC % for the quarter that ended in Mar. 2024 was -542.27%. Bluejay Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -603.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bluejay Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1,034.98%.

Bluejay Diagnostics EBIT Historical Data

The historical data trend for Bluejay Diagnostics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bluejay Diagnostics EBIT Chart

Bluejay Diagnostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

-1.63

-1.13

-3.12

-9.32

-10.31

Bluejay Diagnostics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial												-2.68	-2.90	-2.34	-2.39	-2.43

Competitive Comparison of Bluejay Diagnostics's EBIT

For the Medical Devices subindustry, Bluejay Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bluejay Diagnostics's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bluejay Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bluejay Diagnostics's EV-to-EBIT falls into.

Bluejay Diagnostics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-10.06 Mil.

Bluejay Diagnostics (NAS:BJDX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bluejay Diagnostics's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-9.712 * ( 1 - 0% )	/	( (1.811	+	1.771)	/ 2 )
=	-9.712	/	1.791
=	-542.27 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	4.869	-	1.608	-	( 2.209	-	max(0, 1.771	-	3.221	+	2.209	))
=	1.811

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.075	-	1.38	-	( 2.661	-	max(0, 1.526	-	3.45	+	2.661	))
=	1.771

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Bluejay Diagnostics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-9.712	/	( ( (1.619 + max(-0.596, 0))	+	(1.6 + max(-0.591, 0)) )	/	2 )
=	-9.712	/	( ( 1.619	+	1.6 )	/	2 )
=	-9.712	/	1.6095
=	-603.42 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	1.012)	-	(1.608	+	0	+	-2.2204460492503E-16)
=	-0.596

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.789)	-	(1.38	+	0	+	2.2204460492503E-16)
=	-0.591

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bluejay Diagnostics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-10.06	/	-0.972
	=	1,034.98 %

Bluejay Diagnostics EBIT Related Terms

Thank you for viewing the detailed overview of Bluejay Diagnostics's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bluejay Diagnostics (Bluejay Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bluejay Diagnostics Inc (NAS:BJDX) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

360 Massachusetts Avenue, Suite 203, Acton, MA, USA, 01720

Website

https://www.bluejaydx.com

Bluejay Diagnostics Inc is a medical diagnostics company. It is engaged in developing, manufacturing, and marketing of clinical diagnostic products that improve the quality of medical diagnoses. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings. The company is a provider of rapid tests for infectious, inflammatory, and metabolic diseases by the Symphony platform.

Executives

Svetlana Dey	director, 10 percent owner	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Indranil Dey	director, 10 percent owner, officer: Chief Technology Officer	360 MASSACHUSETTS AVENUW, SUITE 203, ACTON MA 0170
Frances P Scally	officer: CFO	66 MELANIE LANE, SYOSSET NY 11791
Jason Cook	officer: Chief Technology Officer	360 MASSACHUSETTS AVE, SUITE 203, ACTON MA 01720
Kenneth R Fisher	officer: Chief Financial Officer	67 PROSPECT STREET, PEABODY MA 01960
Douglas Clark Wurth	director, 10 percent owner	4265 SAN FELIPE, SUITE 603, HOUSTON TX 77027
Gordon Winston Kinder	officer: Chief Financial Officer	360 MASSACHUSETTS AVENUE, SUITE 203, ACTON MA 01720
Gary G Gemignani	director	C/O IASO PHARMA INC., 12707 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Fred S Zeidman	director	109 NORTH POST OAK LANE, SUITE 422, HOUSTON TX 77024
Donald R Chase	director	39 TIMBER RIDGE RD., WEST SPRINGFIELD MA 01089